Bifogade filer
Lapatinib Newbury approved by the Swedish Health Authorities
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2023-03-24 11:45:00
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.
Lapatinib is a targeted cancer drug, also known by its brand name Tyverb, that is used to treat certain types of breast cancer, where tumors overexpress HER2.
“Lapatinib is a terrific addition to the existing high-value oncology product portfolio, and we are proud to further strengthen our commitment within oncology. Based on this positive progress, we will proceed to launch this product, within respective markets as soon as regulatory exclusivities and patents allow us.” says Mr Lars Minor CEO of Newbury.
Newbury currently has licensed ten (10) products within oncology and plan to offer treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer and thyroid cancer).